Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of IAH0968 with or without CAPEOX in HER2-expressing advanced or metastatic solid tumors and gastric cancer
CTR20242516Phase 3Active
- Sponsor
- SUNHO BioPharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of IAH0968 in Nonhematologic neoplasms, gastric cancer (GC), gastroesophageal junction adenocarcinoma, colorectal cancer (CRC), sponsored by SUNHO BioPharmaceutical. Started Aug 2025; status: active.
02
Drugs
IAH0968
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)gastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20242516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242516.